State of California - Department of Justice - Attorney General's Office - Proposition 65 Enforcement Reporting

FORM JUS 1502 (03-01) Attention: Prop 65 Coordinator, 1515 Clay Street, Suite 2000, Oakland, CA 94612

PRIVATE ENFORCEMENT FILING - Health and Safety Code section 25249.7(e) and (f)

### REPORT OF ENTRY OF JUDGMENT

Please	print or type required information	Original Filing	Supplemental	l Filing	Corrected Filing			
Z	PLAINTIFF(S) Shefa LMV LLC  DEFENDANT(S) INVOLVED IN JUDGMENT Blistex, Inc.							
PARTIES TO THE ACTION	Briscex, The.							
CASE	COURT DOCKET NUMBER CIV 1503341			COURTNA Mari	ME n Superior Co	urt		
SHORT CASE NAME Shefa v. Concept II Cosmetics								
	INJUNCTIVE RELIEF  Reformultion							
REPORT INFO	PAYMENT: CIVIL PENALTY \$10,000.00  DATE SUBMITTED TO COURT  5 /12/2016	PAYMENT: ATTORN \$50,000.0	00	O IFYES,	DATE SETTLEMENT WAS	For Internal Use Only		
<u>«</u>	COPY OF JUDGMENT MUST BE ATTACHED							
FILER INFO	NAMEOFCONTACT Daniel N. Greenbaum, Esq.							
	ORGANIZATION Law Office of Daniel Greenbaum					TELEPHONE NUMBER ( 818 ) 809-2199		
	7120 Hayvenhurst Av	FAX NUMBER (424) 243-7689						
	CITY Van Nuys	STATE 9 7406			E-MAIL ADDRESS dgreenbaumlawfirm.com			

**FILING INSTRUCTIONS:** This form can be completed online and printed. If electronic filing is not available, mail the completed form with a copy of the judgment to the attention of the Prop 65 Coordinator at the address shown above. If you need additional space to complete this form please use an attachment.



# JUL 0 8 2016

JAMES M. KIM, Court Executive Officer MARIN COUNTY SUPERIOR COURT By: J. Berg, Deputy

# LAW OFFICE OF DANIEL N. GREENBAUM Daniel N. Greenbaum, Esq. (SBN 268104) The Hathaway Building 7120 Hayvenhurst Avenue Suite 320 Van Nuys, CA 91406 Telephone: (818) 809-2199 Facsimile: (424) 243-7689 Email: dgreenbaum@greenbaumlawfirm.com

Attorney for Plaintiff SHEFA LMV, LLC

ARNOLD & PORTER LLP

Trenton H. Norris, Esq.
Stephanie I. Fine, Esq.

Three Embarcadero Center

**10** | 10<sup>th</sup> Floor

San Francisco, CA 94111
Talaphana: (415) 471 330

Telephone: (415) 471-3303
Facsimile: (415) 471-3400

Email: trent.norris@aporter.com
Email: stephanie.fine@aporter.com

Attorneys for Defendant BLISTEX, INC.

1516

17

18

14

1

2

3

4

5

6

7

### SUPERIOR COURT OF THE STATE OF CALIFORNIA

### **COUNTY OF MARIN**

### UNLIMITED CIVIL JURISDICTION

19 20

SHEFA LMV, LLC.,

VS.

through 50, inclusive,

Plaintiff,

CONCEPT II COSMETICS, LLC; and DOES 1

21

22

23

24

25

26

27

28

21

Defendants.

Case No. CIV 1503341

[PROPOSED] CONSENT JUDGMENT AS TO BLISTEX INC.

Action Filed: Sept. 10, 2015

BY FAX

Page 1

[PROPOSED] CONSENT JUDGMENT AS TO BLISTEX, INC.

1

3 4

5

6

7

8 9

10

11 12

13

14

15 16

17

18

19

20

21 22

23

24 25

26

27

28

## INTRODUCTION

### 1.1 **Parties**

This consent judgment ("Consent Judgment") is entered into by and between plaintiff Shefa LMV, LLC ("Shefa" or "Plaintiff") and Blistex Inc. ("Blistex" or "Settling Defendant"), with Shefa and Blistex individually referred to as a "Party" and collectively as the "Parties."

### 1.2 **Plaintiff**

Shefa is a limited liability company in California that seeks to promote awareness of exposures to toxic chemicals and to improve human health by reducing or eliminating hazardous substances contained in consumer products.

### 1.3 **Settling Defendant**

Blistex employs ten or more persons and is a person in the course of doing business for purposes of the Safe Drinking Water and Toxic Enforcement Act of 1986, Health and Safety Code section 25249.6 et seq. ("Proposition 65").

### 1.4 **Products Covered**

The products covered by this Consent Judgment are lip protectors alleged to contain benzophenone that are manufactured, sold, or distributed for sale in California by Blistex including, but not limited to, Blistex Five Star Lip Protection (UPC 041388002231) (collectively, "Covered Products").

### 1.5 **General Allegations**

Shefa alleges that Blistex manufactures, imports, sells, or distributes, for sale in the state of California, lip protectors that contain benzophenone without first providing a clear and reasonable warning required by Proposition 65. Benzophenone (CAS # 119-61-9) is a chemical listed under Proposition 65 as a chemical "known to the state to cause cancer" as Proposition 65 defines that term. 27 CCR 25000. Blistex denies these allegations.

### 1.6 **Notice of Violation**

On March 26, 2015, Shefa served Blistex, others, and the requisite public enforcement agencies with a 60-Day Notice of Violation ("Notice") alleging that Blistex violated Proposition

65 when it failed to warn its customers and consumers in California that the Covered Products expose users to benzophenone. To the best of the Parties' knowledge, no public enforcer has commenced and is diligently prosecuting the allegations set forth in the Notice.

# 1.7 Settlement Agreement

The Parties previously executed an agreement dated March 24, 2016 to settle the claims asserted in the Notice ("Settlement Agreement"). The Parties agree that upon the Parties' execution of this Consent Judgment, the Settlement Agreement shall be rescinded.

Pursuant to the Settlement Agreement, Blistex previously remitted the payments specified in Section 3. The Parties agree that the Law Office of Daniel N. Greenbaum shall retain in trust all funds paid under the Settlement Agreement -- other than the civil penalty payment to be distributed to OEHHA -- pending the Court's consideration of the motion to approve this Consent Judgment. Should this Consent Judgment not be approved, the funds shall be returned to Blistex within ten (10) business days unless otherwise agreed by the Parties. Upon entry of this Consent Judgment, the funds previously paid by Blistex pursuant to the Settlement Agreement shall be deemed to satisfy all the monetary requirements of this Consent Judgment, as set forth in Section 3.

## 1.8 Complaint

On September 10, 2015, Shefa filed a complaint in the Superior Court in and for the County of Marin against Concept II Cosmetics, LLC and DOES 1-150, alleging violations of California Health & Safety Code § 25249.6, based on exposures to benzophenone contained in certain products containing sunscreen sold in the State of California (the "Complaint"). On April 26, 2016, Shefa filed a DOE Amendment under Code Civ. Proc. § 474, listing Blistex as DOE 23.

### 1.9 No Admission

Blistex denies the material, factual, and legal allegations contained in the Notice and Complaint and maintains that all of the products it has manufactured, sold, or distributed for sale in California, including the Covered Products, have been, and are, in compliance with all laws.

 Nothing in this Consent Judgment shall be construed as an admission by Blistex of any fact, finding, conclusion of law, issue of law, or violation of law; nor shall compliance with this Consent Judgment constitute or be construed as an admission by Blistex of any fact, finding, conclusion of law, issue of law, or violation of law, the same being specifically denied by Blistex. This section shall not, however, diminish or otherwise affect Blistex's obligations, responsibilities, and duties under this Consent Judgment.

### 1.10 Consent to Jurisdiction

For purposes of this Consent Judgment only, the Parties stipulate that this Court has jurisdiction over Settling Defendant as to the allegations in the Complaint, that venue is proper in the County of Marin, the Settling Defendant agrees that it employs or has employed ten or more persons during time periods relevant to the Complaint and that this Court has jurisdiction over the Parties to enter and enforce the provisions of this Consent Judgment pursuant to Proposition 65 and Code of Civil Procedure § 664.6.

### 1.11 Effective Date

For purposes of this Consent Judgment, the term "Effective Date" shall mean the date the Consent Judgment is approved and entered by the Court.

### 2. INJUNCTIVE RELIEF: COMPLIANT PRODUCTS AND WARNINGS

## 2.1 Reformulation Standards

"Reformulated Products" are defined as those Covered Products containing benzophenone in concentrations less than or equal to 12.5 parts per million ("ppm") when analyzed pursuant to a scientifically reliable application of U.S. Environmental Protection Agency testing methodologies 3580A and 8270C or any other scientifically reliable methodology for determining the benzophenone content in a substance of the form of the Covered Products herein. As of the date of execution of this Consent Judgment, Blistex represents that it has actively engaged its suppliers of raw materials to comply with its reformulation efforts. Commencing on March 24, 2016, and continuing thereafter, Blistex shall not order, or cause to be ordered, the raw ingredient octocrylene, used to manufacture the

Covered Products to be distributed, sold and/or offered for sale in California, unless the octocrylene contains levels of benzophenone that will result in benzophenone concentrations in the Covered Products that are below the level stated above. In order to ensure that the process for verifying that the octocrylene suppliers meet Blistex's standards, Blistex shall obtain an initial Certificate of Analysis ("COA") from each supplier of octocrylene, and thereafter obtain a COA from each octocrylene supplier for each subsequent shipment, and keep the COAs for a period of two years from receipt. Copies of these COAs shall be provided to Shefa upon request. Unless Blistex chooses to eliminate the use of octocrylene in the Covered Products, then Blistex shall conduct at least one test per year for benzophenone in the Covered Products for a period of two (2) years, and test results shall be provided to Shefa upon request.

### 2.2 Reformulation

Commencing on March 24, 2016, and continuing thereafter, Blistex shall not manufacture, or cause to be manufactured, for sale in California, or order for distribution or sale in California, Covered Products unless they are Reformulated Products pursuant to Section 2.1 above.

### 3. MONETARY SETTLEMENT TERMS

# 3.1 Civil Penalty Payments

Blistex agrees to an assessment of \$10,000 as a civil penalty. Such penalty payment shall be allocated according to Health and Safety Code section 25249.12(c)(1) and (d), with 75% of the penalty amount paid to the California Office of Environmental Health Hazard Assessment ("OEHHA") and the remaining 25% of the penalty paid to Shefa. The civil payment is allocated as follows: (a) \$7,500 payable to OEHHA; and (b) \$2,500 payable to Shefa.

### 3.2 Reimbursement of Attorney Fees and Costs

The Parties reached an accord on the compensation due to Shefa and its counsel under general contract principles and the private attorney general doctrine codified at Code of Civil Procedure section 1021.5 for all work performed in this matter. Under these legal principles, \$50,000 shall be payable by Blistex to the Law Office of Daniel N. Greenbaum for all fees and

costs through execution of this Consent Judgment, including fees and costs incurred investigating, bringing this matter to the attention of Blistex's management, and negotiation of this settlement.

### 4. CLAIMS COVERED AND RELEASED

## 4.1 Shefa's Public Release of Blistex

This Consent Judgment is a full, final, and binding resolution between Shefa and Blistex of any violation of Proposition 65 that was or could have been asserted by Shefa, acting on behalf of itself and in a representative capacity in the public interest under Cal. Health & Safety Code § 25249.7, against Blistex, its parents, subsidiaries, affiliated entities under common ownership, manufacturers, suppliers, directors, officers, employees, attorneys, and the predecessors, successors, or assigns of each of them, and each entity to whom Blistex directly or indirectly distributes or sells the Covered Products, including, without limitation, downstream distributors, wholesalers, customers, retailers, franchisees, cooperative members, and licensees ("Releasees"), based on failure to warn of alleged exposures to benzophenone from Covered Products manufactured, sold or distributed for sale in California by Blistex prior to the Effective Date. The release in this Section 4.1 applies to all Covered Products that Blistex manufactured, distributed, or sold prior to the Effective Date, regardless of the date any other Releasee distributes or sells the Covered Products.

Upon entry of this Consent Judgment by the Court, going forward, Blistex's compliance with the terms of this Consent Judgment shall be deemed to constitute compliance with Proposition 65 by Blistex or any other Releasee with respect to benzophenone in Covered Products manufactured, sold, or distributed for sale in California by Blistex on and after March 24, 2016.

### 4.2 Shefa's Individual Release of Claims

In further consideration of the promises and agreements herein contained, Shefa, on its own behalf and on behalf of its past and current agents, representatives, attorneys, successors, and/or assignees, hereby waives all rights to institute or participate in, directly or indirectly, any

form of legal action, and releases all claims that it may have against Blistex and Releasees, including, without limitation, all actions and causes of action, suits, liabilities, demands, obligations, damages, costs, fines, penalties, losses, or expenses, including, without limitation, investigation fees, expert fees, and attorneys' fees arising under Proposition 65 for unwarned exposures to benzophenone from Covered Products manufactured, sold, or distributed for sale in California by Blistex prior to the Effective Date. The releases in Section 4.2 are provided in Shefa's individual capacity and are not releases on behalf of the public.

### 4.3 Blistex's Release of Shefa

Blistex, on its own behalf and on behalf of its past and current agents, representatives, attorneys, successors, and assignees, hereby waives any and all claims that it may have against Shefa and its attorneys and other representatives, for any and all actions taken or statements made by Shefa and its attorneys and other representatives, whether in the course of investigating claims, otherwise seeking to enforce Proposition 65 against it in this matter, or with respect to the Covered Products.

### 5. COURT APPROVAL

This Consent Judgment is not effective until it is approved and entered by the Court and shall be null and void if, for any reason, it is not approved and entered by the Court within 90 days after it has been fully executed by the Parties, or by such additional time as the Parties may agree in writing.

### 6. SEVERABILITY

If, subsequent to the execution of this Consent Judgment, any provision of this Consent Judgment is held by a court to be void or unenforceable, or the Parties agree to modify any terms due to comments from the Office of the Attorney General or after a hearing before the Court in connection with Shefa's Motion to Approve, or for other good cause, each Party to be bound by any such modified terms must re-execute the modified Consent Judgment and such modified Consent Judgment then shall be presented by Shefa to the Court for approval; provided, however, that if a provision of this Consent Judgment declared void or unenforceable is material

to the Party for whom such term provided a benefit or protection, that Party can seek other remedies, including, without limitation, rescission or reformation, based on the provision being declared void or unenforceable.

### 7. GOVERNING LAW

The terms of this Consent Judgment shall be governed by the laws of the State of California and apply within the State of California. Benzophenone is listed pursuant to Proposition 65 as a chemical that is known to the State of California to cause cancer. In the event that Proposition 65 is repealed or is otherwise rendered inapplicable by reason of law generally, or as to the Covered Products, including without limitation the delisting of benzophenone, then Blistex may provide written notice to Shefa of any asserted change in the law, and with the exception of Sections 3.1 and 3.2 above, have no further obligations pursuant to this Consent Judgment, with respect to, and to the extent that, the Covered Products are so affected. None of the terms of this Consent Judgment shall have any application to Covered Products sold outside of the State of California.

### 8. NOTICE

Unless specified herein, all correspondence and notices required to be provided pursuant to this Consent Judgment shall be in writing and sent by: (i) personal delivery; (ii) first-class, registered or certified mail, return receipt requested; or (iii) a recognized overnight courier on any Party by the other at the following addresses:

To Blistex:

To Shefa:

Chief Operating Officer Blistex Inc. 1800 Swift Drive Oak Brook, Illinois 60523-1574 Daniel N. Greenbaum Law Office of Daniel N. Greenbaum 7120 Hayvenhurst Ave., Suite 320 Van Nuys, CA 91406

With a copy to:

Trenton H. Norris Arnold & Porter LLP Three Embarcadero Center, 10th Floor San Francisco, CA 94111-4024

27

25

26

28

Page 8

Any Party may, from time to time, specify in writing to the other Party a change of address to which all notices and other communications shall be sent.

# 9. COUNTERPARTS; FACSIMILE AND PDF SIGNATURES

This Consent Judgment may be executed in counterparts, and by facsimile or portable document format (PDF) signature, each of which shall be deemed an original, and all of which, when taken together, shall constitute one and the same document.

# 10. COMPLIANCE WITH HEALTH & SAFETY CODE § 25249.7(f)

Plaintiff agrees to comply with the reporting form requirements referenced in California Health & Safety Code § 25249.7(f).

### 11. POST EXECUTION ACTIVITIES

11.1 The Parties acknowledge that, pursuant to California Health & Safety Code § 25249.7(f), Shefa is obligated to file a noticed motion to obtain judicial approval of this Consent Judgment. Upon the Parties' execution of this Consent Judgment, Shefa promptly shall proceed to submit this Consent Judgment to the Court with a motion seeking Court approval.

### 12. MODIFICATION

- judgment entered into by Shefa involving another party, or any future court-approved consent judgment entered into by any enforcer of Proposition 65 involving another party, sets out a reformulation or compliance standard that is less stringent than that in Section 2.1 above for benzophenone in substantially similar lip protectant products, then upon written notice to Shefa, Blistex is entitled to a corresponding modification to the corresponding standard set forth in section 2.1 of this Consent Judgment, with regard to the Covered Products.
- 12.2 In the event OEHHA establishes a safe harbor No-Significant Risk Level ("NSRL") for benzophenone, which Blistex asserts would allow for the Covered Products to contain levels of benzophenone in amounts greater than those set forth above in Section 2.1, then Blistex may provide written notice to Shefa of any such assertion and the Parties shall confer within 30 days to attempt to agree upon modification of this Consent Judgment. Should such

attempts at informal resolution of a modification fail, and in the event Blistex still intends to change its reformulation obligations, Blistex will provide written notice to Shefa of its intent to adopt a modified compliance standard. Upon receipt of Blistex's notice, Shefa shall have the right to enforce the terms and conditions contained in the Consent Judgment by motion or any other available remedy at law, with the sole issue to be adjudicated being the technical question of whether the NSRL would allow for a higher benzophenone content in the Covered Products than that set forth in Section 2.1.

12.3 This Consent Judgment may only be modified by a written instrument executed by the Party or Parties to be bound thereby, and after approval by the Court upon a noticed motion. Any motion to modify shall be served on all Parties and the Office of the Attorney General.

### 13. DISPUTE RESOLUTION

If Shefa determines at a future date that a violation of this Consent Judgment has occurred, Shefa shall provide notice to Blistex. Prior to bringing any action to enforce any requirement of this Consent Judgment, the party alleging a violation of this Consent Judgment shall provide the other party with written notice of the grounds for such allegation together with all supporting information as well as a complete demand for the relief sought. The Parties shall then meet and confer regarding the basis for the allegation in an attempt to resolve the matter informally, including providing the party alleged to be in violation with a reasonable opportunity of at least thirty (30) days to cure any alleged violation. Should such attempts at informal resolution fail, the party alleging a violation may file its lawsuit seeking the proposed relief.

### 14. AUTHORIZATION

The undersigned are authorized to execute this Consent Judgment on behalf of their respective Parties and have read, understood and agree to all of the terms and conditions of this Consent Judgment.

\_ .

1	AGREED TO:	AGREED TO:
2 3 4	Date:5/10/2016  By:Shefa LMV, LLC	Date: 5-9-16  By: Settling Defendant: Blistex Inc.
5		
6		
7		
8		
9.		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28	IDD ODOSEDI CONSENT IIII	Page 11 DGMENT AS TO BLISTEX, INC JCCP No. 4765

1	ORDER AND JUDGMENT						
2 Based	Based upon the stipulated Consent Judgment between Shefa LMV, LLC and Blistex, Inc						
the settlement	the settlement is approved and the clerk is directed to enter judgment in accordance with the						
terms herein.	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						
5	JUL 0 8 2016						
Dated:	•	DAIU BE LIAAKENDON					
,		PAUL M. HAAKENSON					
		Judge of the Superior Court					
		<b>5</b>					
		•					
		age <b>12</b> DGMENT AS TO BLISTEX, INC.					